BiotechTube

YHR1705 + YHR1706 + YHR1705+YHR1706

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia

Conditions

Dyslipidemia, Type 2 Diabetes Mellitus

Trial Timeline

Aug 7, 2017 → Sep 19, 2017

NCT ID
NCT03235362

About YHR1705 + YHR1706 + YHR1705+YHR1706

YHR1705 + YHR1706 + YHR1705+YHR1706 is a phase 1 stage product being developed by Yuhan for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03235362. Target conditions include Dyslipidemia, Type 2 Diabetes Mellitus.

What happened to similar drugs?

15 of 20 similar drugs in Dyslipidemia were approved

Approved (15) Terminated (3) Active (3)
✅Pitavastatin + PravastatinEli LillyApproved
✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
✅rosuvastatin + placebo + rosuvastatin + atorvastatinAstraZenecaApproved
✅FluvastatinNovartisApproved
✅Fluvastatin extended release, fenofibrate + Fixed combination simvastatin/ezetimibeNovartisApproved
✅FluvastatinNovartisApproved
✅Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03235362Phase 1Completed

Competing Products

20 competing products in Dyslipidemia

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
29
Pitavastatin + PravastatinEli LillyApproved
43
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
43
YH14755 + Metformin + RosuvastatinYuhanPhase 3
40
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
33
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
29
MevalotinDaiichi SankyoPre-clinical
26
PravastatinDaiichi SankyoPre-clinical
26
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
29
LY3885125 + PlaceboEli LillyPhase 1
21
LY3561774 + PlaceboEli LillyPhase 1
29
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
35
LY3561774 + PlaceboEli LillyPhase 2
35
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
35
EvacetrapibEli LillyPhase 1
29
PPAR alpha + placeboEli LillyPhase 2
35
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
29
ABT-335 + RosuvastatinAstraZenecaPhase 1
29
AZD6615 + PlaceboAstraZenecaPhase 1
21
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
29